According to Merrimack Pharmaceuticals's latest financial reports the company has โฌ0.21 Billion in cash and cash equivalents.
A companyโs cash on hand also refered as cash/cash equivalents (CCE) and Short-term investments, is the amount of accessible money a business has.
Year | Cash on Hand | Change |
---|---|---|
2023-12-31 | โฌ17.07 M | -5.78% |
2022-12-31 | โฌ18.12 M | 44.5% |
2021-12-31 | โฌ12.54 M | 9.88% |
2020-12-31 | โฌ11.41 M | -22.89% |
2019-12-31 | โฌ14.8 M | -76.25% |
2018-12-31 | โฌ62.3 M | -19.99% |
2017-12-31 | โฌ77.87 M | 280.58% |
2016-12-31 | โฌ20.46 M | -87.95% |
2015-12-31 | โฌ0.16 B | 66.46% |
2014-12-31 | โฌ0.10 B | -9.26% |
2013-12-31 | โฌ0.11 B | 35.2% |
2012-12-31 | โฌ83.12 M | 113.95% |
2011-12-31 | โฌ38.85 M | 68.26% |
2010-12-31 | โฌ23.09 M | -43.34% |
2009-12-31 | โฌ40.75 M |
Company | Cash on Hand | differencediff. | Country |
---|---|---|---|
![]() Sanofi SNY | โฌ7.48 B | 3,441.59% | ๐ซ๐ท France |
![]() AVEO Oncology
AVEO | โฌ66.99 M | -68.29% | ๐บ๐ธ USA |
![]() Geron GERN | โฌ0.34 B | 62.58% | ๐บ๐ธ USA |
![]() Clovis Oncology CLVS | โฌ50.48 M | -76.11% | ๐บ๐ธ USA |
![]() Eterna Therapeutics ERNA | โฌ1.66 M | -99.21% | ๐บ๐ธ USA |